GMI 2093
Alternative Names: GMI-2093Latest Information Update: 16 Jan 2024
At a glance
- Originator GlycoMimetics
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action Galectin 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Fibrosis
Most Recent Events
- 16 Jan 2024 GMI 2093 is still in preclinical trials in Cancer in USA (PO) (GlycoMimetics pipeline, January 2024)
- 16 Jan 2024 GMI 2093 is still in preclinical trials in Fibrosis in USA (PO) (GlycoMimetics pipeline, January 2024)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in USA (PO)